This paper is based on presentations given during a symposium and related sessions at the 2003 European Burns Association meeting by: Professor Robert E Burrell, Department of Chemical and Materials Engineering, University of Alberta, Edmonton, Alberta, Canada Professor Robert Demling, Professor of Surgery, Harvard Medical School, Boston, MA, USA Dr Simone Pancani, Paediatric Burn Unit, Department of Paediatric Surgery, Anna Meyer Children's Hospital, Florence, Italy Dr Anthony Papp, Burn Unit, Kuopio University Hospital, Finland Dr Ole Strand, Paediatric Surgery, Astrid Lindgren Children's Hospital, Karolinska Hospital, Stockholm, Sweden Dr Veronique Voinchet, Paediatric Burns Unit, Marseille, France The symposium was chaired by Dr Thomas Sjoberg of the University Hospital, Tromso, Norway Silver is an effective antimicrobial agent, but older silver-containing formulations are rapidly inactivated by the wound environment, requiring frequent replenishment. These older formulations may also be pro-inflammatory and may delay healing. Acticoat™ (Smith & Nephew, Hull, UK) is a relatively new form of silver antimicrobial barrier dressing which helps avoid the problems of earlier agents. It has rapid and sustained bactericidal activity, and because of this may reduce inflammation and promote healing. Despite extensive testing and clinical experience, no evidence has emerged of resistance or cytotoxicity to nanocrystalline silver. This article collects together a number of presentations that were given at the 2003 European Burns Association Meeting on the use of Acticoat™ in the management of burns.